Weight-Loss Drug Wegovy Shows Promise for Obese Children in New Study
A new international study found that the weight-loss drug Wegovy significantly reduced obesity in children aged six to 11, with nearly 80% achieving a 10% BMI reduction. Approximately 40% of treated children were no longer considered obese after 68 weeks. Three Israeli medical centers participated in the study, which could lead to new treatment options for young obese children.
הידיעה ב-5 שורות · תקציר של baba
- Wegovy significantly reduced obesity in children aged 6-11 in a new international study.
- Nearly 80% of treated children achieved at least a 10% BMI reduction.
- About 40% of children on Wegovy no longer met obesity criteria after 68 weeks.
- 16 children from Israel participated in the study across three medical centers.
- Wegovy is already available in Israel for adolescents aged 12-18.
A new international study involving 167 children aged six to 11, including 16 from Israel, suggests that the weekly injection of the weight-loss drug Wegovy (semaglutide) could offer a new treatment option for severely obese young children, leading to significant reductions in Body Mass Index (BMI).
The analysis, which assessed the drug's effectiveness assuming treatment adherence, found that nearly 80% of the children treated with Wegovy achieved at least a 10% decrease in BMI, compared to none in the placebo group. Furthermore, approximately 40% of the children on the drug no longer met the definition of obesity after 68 weeks.
In Israel, three medical centers participated in the research: Schneider, Shamir, and Rambam. Last year, Wegovy was added to Israel's national health basket for treating adolescents aged 12-18, provided they meet specific medical criteria.
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
מרכז 2ימין 1
לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.
